Compare NUCL & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUCL | IPSC |
|---|---|---|
| Founded | 2023 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.2M | 367.6M |
| IPO Year | 2026 | 2021 |
| Metric | NUCL | IPSC |
|---|---|---|
| Price | $5.99 | $1.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 248.6K | ★ 376.0K |
| Earning Date | 05-22-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $4.63 | $0.44 |
| 52 Week High | $14.22 | $2.97 |
| Indicator | NUCL | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 41.99 |
| Support Level | $5.14 | $1.92 |
| Resistance Level | $6.35 | $2.39 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 0.00 | 13.89 |
Eagle Nuclear Energy Corp is a next-generation nuclear energy company that seeks to combine domestic uranium exploration and development with proprietary small modular reactor (SMR) technology. It holds the rights to the mineable, measured and indicated uranium deposit in the United States, referred to as the Aurora Uranium Project, located in southeastern Oregon. The Aurora Uranium Project includes the Aurora deposit, with an estimated 37.73 million pounds of near-surface uranium and the adjacent Cordex Zone Eagle's SMR technology. Eagle's mission is to supply uranium to the growing nuclear energy industry and play a role in the global transition to clean, reliable, and affordable energy.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.